Updated clinical guidance outlines family planning, prenatal monitoring, and fertility care for patients living with cystic fibrosis.
RT’s Three Key Takeaways:
- Rising Conception Rates: Pregnancy rates nearly doubled among women with cystic fibrosis following the introduction of triple-combination modulator therapy, prompting new clinical recommendations for reproductive care across the lifespan.
- Multidisciplinary Pregnancy Management: Expectant mothers with cystic fibrosis face elevated risks for complications such as premature birth and gestational diabetes, requiring close clinical surveillance of respiratory status, nutritional intake, and blood sugar regulation.
- Persistent Paternal Challenges: Natural conception remains unavailable to more than 95% of men with cystic fibrosis due to congenital absence of the vas deferens, though assisted reproductive techniques and emerging research on prenatal medication exposure present new reproductive pathways.
Advancements in cystic fibrosis (CF) therapeutics have altered clinical considerations for patients, shifting long-term healthcare discussions toward family planning, fertility, and parenthood, according to a researchers from UT Southwestern Medical Center.
Following the approvals of the triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (Trikafta) in the US in 2019 and the UK in 2020, pregnancy rates among women with CF nearly doubled in both nations, according to published clinical data. In response to these demographic shifts, the Cystic Fibrosis Foundation convened an international panel of specialists to establish clinical guidance on CF reproductive healthcare, published in The Lancet Respiratory Medicine in August 2026.
“The pace of change in cystic fibrosis care has been extraordinary. Reproductive health should no longer be an afterthought. Questions that once centered on survival and daily health now increasingly include family planning, pregnancy, and parenthood,” said Raksha Jain, MD, medical director of the adult cystic fibrosis program and professor of internal medicine at UT Southwestern Medical Center.
The consensus recommendations advise clinicians to introduce age-appropriate reproductive education early in care and conduct annual discussions beginning in the adolescent years.
Preconception and Prenatal Respiratory Management
CFTR modulators, first introduced in 2012, improve the cervical environment by altering thick cervical secretions, which facilitates natural conception, according to the report. Because fertility has risen, clinicians emphasize that patients who do not intend to conceive must receive accurate contraceptive counseling. The guidance notes that while the older modulator lumacaftor/ivacaftor can reduce the efficacy of hormonal contraception, most modern CFTR modulators do not interact with hormonal birth control.
For patients intending to conceive, the guidance outlines preconception planning to evaluate:
- Lung function and respiratory status,
- Nutrition and body weight,
- CF-related diabetes and glucose tolerance,
- Prescription medications and dietary supplements, and
- Other systemic CF-related conditions.
Genetic carrier screening should also be offered to patients and their partners before conception to assess inheritance risks and explore assisted reproductive options, such as in vitro fertilization (IVF) with preimplantation genetic testing.
Pregnancy among women with CF remains categorized as high risk, carrying increased rates of premature labor, premature delivery, and gestational diabetes, according to the clinical guidance. Approximately 30% to 40% of adults with CF develop CF-related diabetes, elevating the importance of early metabolic management. The authors recommend administering an oral glucose tolerance test prior to pregnancy, alongside supplemental testing during gestation to lower risks for preeclampsia, preterm birth, and cesarean delivery.
Care teams must also balance maternal stability with fetal exposure. While CFTR modulators cross the placenta, current drug safety data remain reassuring, and discontinuing modulator therapy can trigger maternal clinical decline, according to the authors.
Postpartum and Paternal Considerations
Following delivery, breastfeeding has become an increasingly viable option for patients with CF who maintain proper baseline nutrition and caloric balance. Because CFTR modulators pass into breast milk, ongoing collaboration among pulmonologists, obstetricians, and pediatricians is advised.
The guidance also highlights an unexpected diagnostic hurdle in neonates: infants exposed to CFTR modulators in utero may present without typical clinical signs of CF, such as elevated immunoreactive trypsinogen levels, salty skin, neonatal intestinal obstruction, or severe jaundice. Consequently, traditional newborn screening panels may fail to detect CF, making post-birth genetic testing necessary when risk factors exist.
For male patients, natural conception barriers persist. More than 95% of men with CF are unable to conceive naturally due to congenital bilateral absence of the vas deferens, according to the report. While sperm retrieval paired with IVF remains standard for biological fatherhood, recent case reports indicate that fetal exposure to maternal CFTR modulators during organogenesis has resulted in some male infants being born with an intact vas deferens.
“The conversation is no longer just about managing cystic fibrosis today. Increasingly, it’s about helping patients plan for the life they want to build tomorrow,” said Jain, who served as corresponding author for the guidelines.
